Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1200537-40-1 | MDL No. : | MFCD22572270 |
Formula : | C14H25BN2O3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | LTQJJMKARMAXCA-UHFFFAOYSA-N |
M.W : | 280.17 | Pubchem ID : | 58004614 |
Synonyms : |
|
Num. heavy atoms : | 20 |
Num. arom. heavy atoms : | 5 |
Fraction Csp3 : | 0.79 |
Num. rotatable bonds : | 4 |
Num. H-bond acceptors : | 4.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 80.6 |
TPSA : | 45.51 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | Yes |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.72 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 1.81 |
Log Po/w (WLOGP) : | 1.45 |
Log Po/w (MLOGP) : | 0.58 |
Log Po/w (SILICOS-IT) : | 1.55 |
Consensus Log Po/w : | 1.08 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.64 |
Solubility : | 0.644 mg/ml ; 0.0023 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.39 |
Solubility : | 1.15 mg/ml ; 0.00412 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.72 |
Solubility : | 0.0536 mg/ml ; 0.000191 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 0.0 |
Synthetic accessibility : | 3.37 |
Signal Word: | Warning | Class: | |
Precautionary Statements: | P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P332+P313-P337+P313-P362-P403+P233-P405-P501 | UN#: | |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
52% | In acetonitrile; at 90℃; for 6h; | Intermediate B22: 1-(2-methoxyethyl)-<strong>[857530-80-4]3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole</strong> (0421) (0422) To a solution of <strong>[857530-80-4]3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole</strong> (0.68 mmol, 150 mg) in CH3CN (5 mL) was added 1-bromo-2-methoxyethane (0.95 mmol, 130.5 mg). The mixture was stirred at 90 C. for 6 h, concentrated under reduced pressure, purified by flash chromatography (silica gel, PE:EA=0-20%, UV254 & UV280 nm) to give the title compound (100 mg, 52%) as a yellow solid. LC-MS: [M+H]+=281.5. |
52% | In acetonitrile; at 90℃; for 6h; | To a solution of 3,5-dimethyl-4-(4,4 ,5,5-tetramethyl-1 ,3 ,2-dioxaborolan-2-yl)- 1H-pyrazole (0.68 mmol, 150 mg) in CH3CN(5mL) was added 1-bromo-2-methoxyethane (0.95 mmol, 130.5mg). The mixture was stirred at 90 C for 6 h, concentrated underreduced pressure, purified by flash chromatography (silica gel, PE:EAO-20%, UV254 & UV280 nm) to give the title compound (100 mg, 52%) as a yellow solid. LC-MS: [M+H] =281.5. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
87% | With tetrakis(triphenylphosphine) palladium(0); sodium hydrogencarbonate In 1,4-dioxane; water at 110℃; for 3.08333h; | 60.1 Step 1: tert-butyl (S)-12-fluoro-4-(l-(2-methoxyethyl)-lH-pyrazol-4-yl)-7a, 13 -dihydro-7 i ll, 2, 4 ]triazolo[4', 3 1, 6jpyrido[3, 2-b ]benzofuro[ 4, 3-fgjfl, 4 ]oxazonine-14(8H)-carboxylale Pd(PPh3)4 (25.9 mg, 0.0224 mmol) was added to a mixture of tert-butyl (S)-4-bromo-12- fluoro-7a, 13-dihydro-7H-[l ,2,4]triazolo[4',3': l,6]pyrido[3,2-b]benzofuro[4,3-fg][l,4]oxazonine- 14(8H)-carboxylate (Example 16; 55.0 mg, 0. 1 12 mmol), l-(2-methoxyethyl)-3,5-dimethyl-4- (4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl) pyrazole (50.2 mg, 0.179 mmol), and NaHC03 (47.0 mg, 0.560 mmol) in 1 ,4-dioxane (1.00 niL) and water (0.200 niL). Nitrogen was bubbled through the mixture for 5 minutes. The mixture was stirred at 1 10 °C for 3 h. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel chromatography (40 g cartridge) eluting with MeOH in DCM (0-10%) to provide tert-butyl (S)-12-fluoro-4-(l-(2-methoxyethyl)-lH-pyrazol-4-yl)-7a,13-dihydro-7H- [l,2,4]triazolo[4',3': l,6]pyrido[3,2-b]benzofuro[4,3-fg][l,4]oxazonine-14(8H)-carboxylate as a solid (56.0 mg, 87 %). IH NMR (400 MHz, edcl3) (rotamers, partial characterization) d 8.66 (s, ill).677 (s, IH), 6.56 (s, 2H), 4.18 (i, j 5.6 Hz, 211).375 (t, I = 5.6 Hz, 2H), 3.33 (s, 3H), 218 (s, 311).213 (s, 311).136 (s, 911) m/z (ES+) IM 11] : 565.5 HPLC tR (A05) = 2.18 min. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 2 steps 1: Cs2CO3 / tetrahydrofuran; lithium hydroxide monohydrate / 16 h / 100 °C / Inert atmosphere 2: dichloromethane; lithium hydroxide monohydrate; 1,4-dioxane / 16 h / 20 °C |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 3 steps 1: Cs2CO3 / tetrahydrofuran; lithium hydroxide monohydrate / 16 h / 100 °C / Inert atmosphere 2: dichloromethane; lithium hydroxide monohydrate; 1,4-dioxane / 16 h / 20 °C 3: Sodium hydrogenocarbonate / lithium hydroxide monohydrate; chloroform / 1 h / 20 °C |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 4 steps 1: Cs2CO3 / tetrahydrofuran; lithium hydroxide monohydrate / 16 h / 100 °C / Inert atmosphere 2: dichloromethane; lithium hydroxide monohydrate; 1,4-dioxane / 16 h / 20 °C 3: Sodium hydrogenocarbonate / lithium hydroxide monohydrate; chloroform / 1 h / 20 °C 4: triethylamine / acetonitrile / 15 h / 70 °C |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 4 steps 1: Cs2CO3 / tetrahydrofuran; lithium hydroxide monohydrate / 16 h / 100 °C / Inert atmosphere 2: dichloromethane; lithium hydroxide monohydrate; 1,4-dioxane / 16 h / 20 °C 3: Sodium hydrogenocarbonate / lithium hydroxide monohydrate; chloroform / 1 h / 20 °C 4: triethylamine / acetonitrile / 16 h / 70 °C |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With Cs2CO3 In tetrahydrofuran; lithium hydroxide monohydrate at 100℃; for 16h; Inert atmosphere; | 102.b Step b: tert-butyl (5-(2-(1-(2-methoxyethyl)-3,5-dimethyl-1H-pyrazol-4-yl)pyrazolo[5,1-b]thiazole-7-carboxamido)-6-methylpyridin-3-yl)carbamate To a solution of tert-butyl (5-(2-bromopyrazolo[5,1-b]thiazole-7-carboxamido)-6-methylpyridin-3-yl)carbamate (2.3 g, 4.4 mmol), 1-(2-methoxyethyl)-3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.6 g, 5.8 mmol),Pd(dppf)Cl2'CH2Cl2(1.1 g, 1.3 mmol) in mixture of THF/H2O (4: 1, 15 mL) was added Cs2CO3(4.4 mg, 14 mmol) at room temperature under N2atmosphere. The mixture was purged with N2with 2 minutes. Then the reaction mixture was stirred at 100°C for 16 hours. After cooling down room temperature, the mixture was filtered off and the filtrate was evaporated to give crude product, which was purified by column chromatography over silica gel (eluent: dichloromethane:methanol = 9:1) to give the title compound tert-butyl (5-(2-(1- (2-methoxyethyl)-3, 5-dimethyl-1H-pyrazol-4-yl)pyrazolo[5,1-b]thi azole-7-carboxamido)-6- methylpyridin-3 -yl)carbamate (1 g, 36%) as a pale brown solid. LCMS (ESI): mass calcd. for C25H31N7O4S, 525.2; m/z found, 526.4 [M+H]+. | |
With Cs2CO3 In tetrahydrofuran; lithium hydroxide monohydrate at 100℃; for 16h; Inert atmosphere; | 102.b Step b: tert-butyl (5-(2-(1-(2-methoxyethyl)-3,5-dimethyl-1H-pyrazol-4-yl)pyrazolo[5,1-b]thiazole-7-carboxamido)-6-methylpyridin-3-yl)carbamate To a solution of tert-butyl (5-(2-bromopyrazolo[5,1-b]thiazole-7-carboxamido)-6-methylpyridin-3-yl)carbamate (2.3 g, 4.4 mmol), 1-(2-methoxyethyl)-3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.6 g, 5.8 mmol),Pd(dppf)Cl2'CH2Cl2(1.1 g, 1.3 mmol) in mixture of THF/H2O (4: 1, 15 mL) was added Cs2CO3(4.4 mg, 14 mmol) at room temperature under N2atmosphere. The mixture was purged with N2with 2 minutes. Then the reaction mixture was stirred at 100°C for 16 hours. After cooling down room temperature, the mixture was filtered off and the filtrate was evaporated to give crude product, which was purified by column chromatography over silica gel (eluent: dichloromethane:methanol = 9:1) to give the title compound tert-butyl (5-(2-(1- (2-methoxyethyl)-3, 5-dimethyl-1H-pyrazol-4-yl)pyrazolo[5,1-b]thi azole-7-carboxamido)-6- methylpyridin-3 -yl)carbamate (1 g, 36%) as a pale brown solid. LCMS (ESI): mass calcd. for C25H31N7O4S, 525.2; m/z found, 526.4 [M+H]+. |
[ 1082503-79-4 ]
1-Ethyl-3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
Similarity: 0.97
[ 1082503-78-3 ]
1-(3,5-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)-2-methylpropan-2-ol
Similarity: 0.95
[ 844891-04-9 ]
1,3,5-Trimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
Similarity: 0.90
[ ]
1-(2-Methoxyethyl)-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
Similarity: 0.98
[ 1082503-79-4 ]
1-Ethyl-3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
Similarity: 0.97
[ 2144759-94-2 ]
3,5-Dimethyl-1-(oxetan-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
Similarity: 0.96
[ 1082503-78-3 ]
1-(3,5-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)-2-methylpropan-2-ol
Similarity: 0.95
[ 2019997-43-2 ]
1-Ethyl-3-methyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
Similarity: 0.91
[ 1082503-79-4 ]
1-Ethyl-3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
Similarity: 0.97
[ 1082503-78-3 ]
1-(3,5-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)-2-methylpropan-2-ol
Similarity: 0.95
[ 844891-04-9 ]
1,3,5-Trimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
Similarity: 0.90
[ 1036991-40-8 ]
1,5-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
Similarity: 0.87